Akeso says ivonescimab met key secondary endpoint in Harmoni-2
Akeso Inc (HKEX:9926) said its ivonescimab met a key secondary endpoint in the Harmoni-2 study.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Akeso’s ivonescimab hits overall survival secondary endpoint in interim Harmoni-2
Akeso Inc (9926) says interim Phase III Harmoni-2 analysis met overall survival as a key secondary endpoint, showing statistically significant and clinically meaningful benefit versus pembrolizumab in first-line PD-L1-positive NSCLC.